Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flunotinib Maleate Combined With Antiviral Therapy in Severe COVID-19
NCT05713279Terminated
- Sponsor
- Zenitar
- Start
- May 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of flonoltinib in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Zenitar. Primary endpoint: Primary efficacy endpoints at 28 days. Started May 2023; status: terminated.
02
Drugs
flonoltinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05713279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05713279.